Clinical trial
Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.
NCT00466089 is registered in ClinicalTrials.gov with Hospital of Navarra as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Randomized Trial of 3D Radiotherapy Versus the Combination of 3D Radiotherapy and Erlotinib (Tarceva®) in Patients With Localized-Unresectable Non-Small Cell Lung Cancer Non Susceptible for Chemotherapy Treatment.
- Lead sponsor
- Hospital of Navarra
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- March 31, 2006
- Completion date
- Not reported
- Enrollment
- 90 (estimated)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.